* Plus Therapeutics Inc PSTV.OQ reported a quarterly
adjusted
loss of 37 cents per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of $-1.00. The mean expectation of four analysts
for the quarter was for a loss of 56 cents per share. Wall
Street expected results to range from -78 cents to -35 cents per
share.
* Revenue rose 17.4% to $1.46 million from a year ago;
analysts
expected $1.52 million.
* Plus Therapeutics Inc's reported EPS for the quarter was a
loss
of 37 cents.
* The company reported a quarterly loss of $2.87 million.
* Plus Therapeutics Inc shares had fallen by 13.7% this
quarter and lost 28.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 0.9%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Plus Therapeutics
Inc is $26.00
This summary was machine generated from LSEG data November 15 at
02:02 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.56 -0.37 Beat
Jun. 30 2024 -0.53 -0.56 Missed
Mar. 31 2024 -1.09 -0.75 Beat
Dec. 31 2023 -1.07 -0.84 Beat